Literature DB >> 33840604

Multidrug resistance: The clinical dilemma of refractory Helicobacter pylori infection.

Chia-Jung Kuo1, Cheng-Han Lee2, Ming-Ling Chang3, Cheng-Yu Lin2, Wey-Ran Lin3, Ming-Yao Su4, Cheng-Hsun Chiu5, Chi-Nan Tseng6, Yu-Shan Wu7, Cheng-Tang Chiu8, Chih-Ho Lai9.   

Abstract

This study investigated the antimicrobial resistance of isolates from patients with refractory Helicobacter pylori. The resistance rate was 34.1% for amoxicillin, 92.7% for clarithromycin, 65.9% for metronidazole, 85.4% for levofloxacin, and 29.3% for rifabutin. Dual resistance to both clarithromycin and levofloxacin was found in 73.2%. The antimicrobial resistance rate of refractory H. pylori was extremely high, which had become a major consideration in therapeutic challenge.
Copyright © 2021. Published by Elsevier B.V.

Entities:  

Keywords:  Antimicrobial susceptibility; Refractory H. pylori; Resistance rate

Mesh:

Substances:

Year:  2021        PMID: 33840604     DOI: 10.1016/j.jmii.2021.03.006

Source DB:  PubMed          Journal:  J Microbiol Immunol Infect        ISSN: 1684-1182            Impact factor:   4.399


  3 in total

1.  1,4-Dihydropyridine as a Promising Scaffold for Novel Antimicrobials Against Helicobacter pylori.

Authors:  Andrés González; Javier Casado; Miyase Gözde Gündüz; Brisa Santos; Adrián Velázquez-Campoy; Cristina Sarasa-Buisan; María F Fillat; Milagrosa Montes; Elena Piazuelo; Ángel Lanas
Journal:  Front Microbiol       Date:  2022-05-25       Impact factor: 6.064

Review 2.  Relationship between Helicobacter pylori infection and gastrointestinal microecology.

Authors:  Wenting Xu; Liming Xu; Chengfu Xu
Journal:  Front Cell Infect Microbiol       Date:  2022-08-18       Impact factor: 6.073

Review 3.  Two-component regulatory systems in Helicobacter pylori and Campylobacter jejuni: Attractive targets for novel antibacterial drugs.

Authors:  Javier Casado; Ángel Lanas; Andrés González
Journal:  Front Cell Infect Microbiol       Date:  2022-08-24       Impact factor: 6.073

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.